China's Biotech Boom
China's biotech surge is marked by a rise in lab monkey prices to $26,000, driven by demand for animal testing in drug development, causing delays and supply chain issues.
Key points
- The price of a research primate in China has risen to 150,000 yuan, approximately $26,000, up from 103,000 yuan in 2025.
- Chinese biotech has seen a record number of deals, public listings, and venture funding, increasing demand for animal testing.
- Cynomolgus monkeys, used in drug testing, take around four years to reach a usable age, causing a supply shortage.
- Contract research labs report delays and rescheduled programs due to animal scarcity, with some reusing monkeys after mandatory rest periods.
- China's pharmaceutical sector has been signing licensing deals with global drugmakers, indicating its pipeline is being taken seriously.
China's biotech industry is experiencing a significant surge, with the price of lab monkeys rising to $26,000. This increase is driven by the growing demand for animal testing in drug development. The country's pharmaceutical sector has seen a record number of deals, public listings, and venture funding, pushing new drug candidates into the testing phase. However, the supply of lab monkeys, particularly Cynomolgus monkeys, cannot keep up with the demand. These monkeys take around four years to reach a usable age, causing a shortage. As a result, contract research labs are experiencing delays and rescheduling programs. Some labs are even reusing monkeys after mandatory rest periods, which can yield weaker data. The scarcity of lab monkeys is a symptom of China's ambition in the biotech industry, with the country's pharmaceutical sector signing licensing deals with global drugmakers at a rapid pace.
Sources
The WireByte editorial team synthesises technology news from multiple primary sources, verifies the facts, and links every source. Articles are produced with AI assistance and reviewed under our editorial policy.